Empagliflozin and the risk of Gout: Analysis from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study

被引：0

作者：

Koeneman, Lisette ^{[1
]}

Tesfaye, Helen ^{[2
]}

Paik, Julie M. ^{[2
]}

Zabotka, Luke E. ^{[2
]}

Htoo, Phyo T. ^{[2
]}

Schmedt, Niklas ^{[3
]}

Seman, Leo ^{[4
,5
]}

Wexler, Deborah J. ^{[6
,7
]}

Patorno, Elisabetta ^{[2
]}

机构：

[1] Lilly Deutschland GmbH, Global Med Affairs, Bad Homburg, Germany

[2] Harvard Med Sch, Dept Med, Brigham & Womens Hosp, Div Pharmacoepidemiol, Boston, MA 02115 USA

[3] Boehringer Ingelheim Int GmbH, Dept Global Epidemio, Ingelheim, Germany

[4] Boehringer Ingelheim Pharmaceut Inc, Ridgefield, CT USA

[5] Clin Dev & Med Affairs, Ridgefield, CT USA

[6] Harvard Med Sch, Massachusetts Gen Hosp, Dept Med, Boston, MA 02115 USA

[7] MGH Diabet Ctr, Div Endocrinol, Boston, MA USA

来源：

INNERE MEDIZIN | 2024年 / 65卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

P21-02

引用

页码：S145 / S145

页数：1

共 50 条

[31] Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
Vistisen, Dorte
Carstensen, Bendix
Elisabetta, Patorno
Lanzinger, Stefanie
Tan, Elise Chia-Hui
Yabe, Daisuke
Kim, Dae Jung
Sheu, Wayne H. -H.
Melzer-Cohen, Cheli
Holl, Reinhard W.
Nunez, Julio
Ha, Kyoung Hwa
Halvorsen, Sigrun
Langslet, Gisle
Karasik, Avraham
Nystrom, Thomas
Niskanen, Leo
Guleria, Sonia
Klement, Riho
Carrasco, Marc
Foersch, Johannes
Shay, Christina
Koeneman, Lisette
Hoti, Fabian
Farsani, Soulmaz Fazeli
Khunti, Kamlesh
Zaccardi, Francesco
Subramanian, Anuradhaa
Nirantharakumar, Krishnarajah
CARDIOVASCULAR DIABETOLOGY, 2023, 22 (01)
[32] Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
Dorte Vistisen
Bendix Carstensen
Patorno Elisabetta
Stefanie Lanzinger
Elise Chia-Hui Tan
Daisuke Yabe
Dae Jung Kim
Wayne H.-H. Sheu
Cheli Melzer-Cohen
Reinhard W. Holl
Júlio Núñez
Kyoung Hwa Ha
Sigrun Halvorsen
Gisle Langslet
Avraham Karasik
Thomas Nyström
Leo Niskanen
Sonia Guleria
Riho Klement
Marc Carrasco
Johannes Foersch
Christina Shay
Lisette Koeneman
Fabian Hoti
Soulmaz Fazeli Farsani
Kamlesh Khunti
Francesco Zaccardi
Anuradhaa Subramanian
Krishnarajah Nirantharakumar
Cardiovascular Diabetology, 22
[33] Cardiovascular Effectiveness of Empagliflozin Compared to Glucagon Like Peptide-1 Receptor Agonists and to Dipeptidyl Peptidase-4 Inhibitors in Older Patients: Results from the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
Htoo, Phyo
Paik, Julie
Tesfaye, Helen
Schneeweiss, Sebastian
Jawaid, Dureshahwar
Wexler, Deborah
Glynn, Robert
Koeneman, Lisette
Luyet, Anouk Deruaz
Najafzadeh, Mehdi
Patorno, Elisabetta
CIRCULATION, 2021, 144
[34] Empagliflozin and the Risk of Heart Failure Hospitalization in Routine Clinical Care A First Analysis From the EMPRISE Study
Patorno, Elisabetta
Pawar, Ajinkya
Franklin, Jessica M.
Najafzadeh, Mehdi
Deruaz-Luyet, Anouk
Brodovicz, Kimberly G.
Sambevski, Steven
Bessette, Lily G.
Ortiz, Adrian J. Santiago
Kulldorff, Martin
Schneeweiss, Sebastian
CIRCULATION, 2019, 139 (25) : 2822 - 2830
[35] Empagliflozin on the risk of retinopathy in patients with type 2 diabetes: Results from the EMPRISE study
Tesfaye, Helen
Htoo, Phyo Than T.
Paik, Julie M.
Zakoul, Heidi
Schmedt, Niklas
Deruaz-Luyet, Anouk
Koeneman, Lisette
Wexler, Deborah
Patorno, Elisabetta
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2023, 32 : 15 - 15
[36] Healthcare Resource Utilization Among Empagliflozin Initiators With and Without Cardiovascular Disease versus DPP4i in a Commercially-Insured Routine Care Population: An Analysis From the Empagliflozin Comparative Effectiveness and Safety (EMPRISE) Study
Najafzadeh, Mehdi
Pawar, Ajinkya
Schneeweiss, Sebastian
Deruaz-Luyet, Anouk
Brodovicz, Kimberly
Ustyugova, Anastasia
Gautam, Nileesa
Patorno, Elisabetta
CIRCULATION, 2019, 140
[37] Empagliflozin on the Risk of Retinopathy in Patients with Type 2 Diabetes-Results from the EMPRISE Study
Tesfaye, Helen
Htoo, Phyo T.
Paik, Julie M.
Zakoul, Heidi
Schmedt, Niklas
Deruaz-Luyet, Anouk
Koeneman, Lisette
Wexler, Deborah J.
Patorno, Elisabetta
DIABETES, 2023, 72
[38] Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study
Seino, Yutaka
Kim, Dae Jung
Yabe, Daisuke
Tan, Elise Chia-Hui
Chung, Wook-Jin
Ha, Kyoung Hwa
Nangaku, Masaomi
Node, Koichi
Klement, Riho
Yasui, Atsutaka
Lei, Wei-Yu
Lee, Sunwoo
Kyaw, Moe H.
Deruaz-Luyet, Anouk
Brodovicz, Kimberly G.
Sheu, Wayne H-H
ENDOCRINOLOGY DIABETES & METABOLISM, 2021, 4 (01)
[39] Empagliflozin and Heart Failure What Can We Learn From EMPRISE?
Verma, Subodh
Lam, Carolyn S. P.
Kosiborod, Mikhail
CIRCULATION, 2019, 139 (25) : 2831 - 2834
[40] Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study
Langslet, Gisle
Nystroem, Thomas
Vistisen, Dorte
Carstensen, Bendix
Grip, Emilie Toresson
Casajust, Paula
Tskhvarashvili, Giorgi
Hoti, Fabian
Klement, Riho
Karlsdotter, Kristina
Tuovinen, Mikko
Ofstad, Anne Pernille
Lajer, Maria
Shay, Christina
Koeneman, Lisette
Farsani, Soulmaz Fazeli
Niskanen, Leo
Halvorsen, Sigrun
JOURNAL OF DIABETES RESEARCH, 2024, 2024

← 1 2 3 4 5 →